selected publications
- Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025 Academic Article GET IT
- Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. Future oncology (London, England). 2025 Academic Article GET IT
- The future of follicular lymphoma management: strategies on the horizon. Blood. 2025 Review GET IT
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Blood.
2023
Academic Article
GET IT
Times cited: 53 - Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Molecular cancer therapeutics. 2022 Academic Article GET IT
-
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Blood.
2022
Academic Article
GET IT
Times cited: 32 -
Biomarker-driven management strategies for peripheral T cell lymphoma.
Journal of hematology & oncology.
2020
Information Resource
GET IT
Times cited: 37 -
CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice.
PloS one.
2016
Academic Article
GET IT
Times cited: 52 -
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
PloS one.
2015
Academic Article
GET IT
Times cited: 94